Researchers reviewed and summarized the safety and efficacy of individual antispasmodics available in North America for the treatment of chronic abdominal pain.
Contracting with outside firms to handle medical billing can be a smart financial move for some medical practices.
The American Gastroenterological Association offered strategies for clinical practice, future research, and policy agenda for the treatment of patients with NAFLD and NASH.
Further research is warranted to understand the potential ways fecal microbiota transplantations may improve patients’ responses to immunotherapy.
One key factor that has developed increasing research interest is the role of a patient’s BMI, specifically those with obesity (BMI > 30 kg/m2), in the development of IBD.